Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-OA PAIN: Orforglipron in Obesity/Overweight and Knee Osteoarthritis
2025-522631-34-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in osteoarthritis (OA), obesity and Overweight comparing Orforglipron once daily with Placebo once daily (2 arms). Primary endpoint: Change from baseline in WOMAC pain subscale score. Planned start Dec 2025; status: authorised.
02
Drugs
orforglipron
03
Conditions
osteoarthritis (OA)obesityOverweight
Beyond the preview
Go deeper on 2025-522631-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522631-34-00.